Out-licensing

Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More

Enhancing the dissolution performance of small and large molecules in a range of dosage forms More

The inactivation approach presented in this technology provides for a safe, non-infectious composition for vaccination against the corresponding agent. More

Uses of a p53 specific microRNA (miRNA): It has been reported that the tumor suppressive mRNA miR-34a (a downstream target of p53) is downregulated in HPV-infected primary keratinocytes. More

Implementation of triplex systems that significantly enhance R434 in vitro activity is offered as an alternative to the antisense oligodeoxynucleotide treatment of cervical cancer More

Novel, non-invasive vaccine strategy to elicit both systemic and mucosal immunity in typically poorly inductive sites More